Bioprocess online published a podcast with us to reveal and publish what was going on behind the scenes, when the pandemic hit, and how Solis BioDyne managed the situation.
Dr. Kadri Artma and Dr. Angela Vaasa are discussing how and why did we stretch the limits. In a really short period of time, we doubled and then tripled our manufacturing capacity. Then we doubled, and then tripled our workforce. Meanwhile, we adopted a host of new platforms to serve the demand of our clients: https://www.bioprocessonline.com/doc/a-scale-up-story-with-solis-biodyne-drs-kadri-artma-and-angela-vaasa-0001
Summer has a way of changing the rhythm of a laboratory. Temperatures rise, team members take well-earned holidays, and deliveries do not always arrive exactly when expected. A shipment may take longer in transit than planned. A package might reach the laboratory on a particularly hot afternoon. With Solis BioDyne’s products, summer heat does not have to bring research to a standstill.
From 2010, Solis BioDyne had stepped into a whole new area of enzyme development. What began as an ambitious R&D project led to FIREScript®, SOLIScript®, RiboGrip® RNase Inhibitor, and the SolisFAST® product line. Find out more about the development process in this blog post.
In high-throughput environments such as diagnostic kit development, pharmaceutical research, and OEM manufacturing, reducing PCR and qPCR costs is rarely as simple as choosing the lowest-priced reagent. Cost per reaction is often the first metric considered, but it does not fully reflect the true financial impact of a workflow.
Modern agriculture increasingly relies on genetic information to accelerate crop improvement. Plant breeders routinely screen thousands of samples to identify genetic variants associated with desirable traits such as yield, disease resistance, drought tolerance, and quality characteristics.
